SUVECALTAMIDE

Search structure
Synonyms:
Status: Phase 2
Entry Type: Small molecule
Molecule Category: UNKNOWN
UNII: MIA4WMP8QN

Structure
InChI Key IQIKXZMPPBEWAD-CQSZACIVSA-N
Smile CC(C)c1ccc(CC(=O)N[C@H](C)c2ccc(OCC(F)(F)F)cn2)cc1
InChI
InChI=1S/C20H23F3N2O2/c1-13(2)16-6-4-15(5-7-16)10-19(26)25-14(3)18-9-8-17(11-24-18)27-12-20(21,22)23/h4-9,11,13-14H,10,12H2,1-3H3,(H,25,26)/t14-/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C20H23F3N2O2
Molecular Weight 380.41
AlogP 4.57
Hydrogen Bond Acceptor 3.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 7.0
Polar Surface Area 51.22
Molecular species NEUTRAL
Aromatic Rings 2.0
Heavy Atoms 27.0

Pharmacology

Action Mechanism of Action Reference
MODULATOR Voltage-gated T-type calcium channel modulator
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Hydrolase
- - - -
Enzyme
- - - -
Ion channel Voltage-gated ion channel Potassium channels Voltage-gated potassium channel
- 4000-8700 - - -
Ion channel Voltage-gated ion channel Voltage-gated calcium channel
- 1.5-2400 - - -
Ion channel Voltage-gated ion channel Voltage-gated sodium channel
- - - - 22
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Lipid-like ligand receptor (family A GPCR) Cannabinoid receptor
- 5340 - - 53
Transcription factor Nuclear receptor Nuclear hormone receptor subfamily 1 Nuclear hormone receptor subfamily 1 group I Nuclear hormone receptor subfamily 1 group I member 2
- - - - 30

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Epilepsy 2 D004827 ClinicalTrials
Essential Tremor 2 D020329 ClinicalTrials
Schizophrenia 2 D012559 ClinicalTrials

Cross References

Resources Reference
ChEMBL CHEMBL1684950
FDA SRS MIA4WMP8QN
PubChem 24765479
SureChEMBL SCHEMBL1065999
CONTENTS